Souhaitez-vous accéder aux communiqués récents ?

CRANBURY, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28,...

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue for both ERT-Naïve and ERT-Switch Patients Patient Reported Outcomes Data...

CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...

Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance 2019 Galafold Revenue Expected to Nearly Double – with Guidance of $160M-$180M Pompe Phase 3 PROPEL Study Expected to Complete...

CRANBURY, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at...

Second Gene Therapy to Enter Clinic at Nationwide Children’s Hospital for Neurologic Lysosomal Storage Disorders Initial Safety is Encouraging with No Serious Adverse Events at One Month CRANBURY,...

CRANBURY, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) --  Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...

Daphne Quimi Promoted to Chief Financial Officer David Clark Joins as Chief People Officer Ellen Rosenberg Promoted to Chief Legal Officer CRANBURY, N.J., Dec. 19, 2018 (GLOBE NEWSWIRE) --...

CRANBURY, N.J. and LONDON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for...

CRANBURY, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at...